Multiple sclerosis (MS) continues to be one of the top specialty management priorities for health plans and pharmacy benefit managers. Payers commonly develop metrics for cost, quality, and utilization on a calendar-year basis. But this “snapshot” approach may miss important elements of both individual and overall patient and treatment dynamics for MS. This report provides insight into potential payment and treatment dynamics in two ways using health insurance claims data.
This report was commissioned by Biogen.